Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 8,035 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: RNA Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older

NCT00979602
View directory record Official record
Conditions
Influenza
Interventions
GSK2340274A, GSK2340273A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
4,048 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
25
States / cities
Mesa, Arizona • Phoenix, Arizona • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Oct 25, 2026, 2:29 PM EDT
Completed No phase listed Observational

Pediatrics HOT COVID-19 Database in NY Tristate

NCT04445402
View directory record Official record
Conditions
Pediatric Cancer, Immune System Disorder, COVID-19, Hemoglobinopathies
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
Up to 21 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 25, 2026, 2:29 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Neural Mechanisms of Fatigue in Post-Acute Sequela of SARS-CoV-2

NCT07278388
View directory record Official record
Conditions
PASC Post Acute Sequelae of COVID 19, Fatigue
Interventions
Physical Fatigue
Behavioral
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 25, 2026, 2:29 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects

NCT01273103
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
200mg [14C]- GSK2248761
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
30 Years to 55 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Not applicable Interventional

Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members

NCT00000703
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, HIV Infections
Interventions
Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride, Cyclophosphamide, Allopurinol, Methotrexate, Cytarabine, Leucovorin calcium, Zidovudine, Dexamethasone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 69 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

COVID-19 Molecular OTC At Home Test

NCT05704803
View directory record Official record
Conditions
COVID-19 Pandemic
Interventions
Diagnostic Test: IN Vitro
Diagnostic Test
Lead sponsor
3EO Health
Industry
Eligibility
2 Years and older
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
4
States / cities
Miami, Florida • Humble, Texas • Kingwood, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 1Phase 2 Interventional Results available

PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)

NCT04347954
View directory record Official record
Conditions
COVID-19
Interventions
Povidone-Iodine 2%, Povidone-Iodine 0.5%, Isotonic saline 0.9%
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Not applicable Interventional

Acupuncture Therapy VS Chiropractor Group Therapy to Reduce Anxiety and Depression.

NCT05936905
View directory record Official record
Conditions
Anxiety Depression, HIV/AIDS
Interventions
Acupuncture, Chiropractic
Other
Lead sponsor
Yo San University of Traditional Chinese Medicine
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 3 Interventional

Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma

NCT00002105
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Doxorubicin hydrochloride (liposomal), Bleomycin sulfate, Vincristine sulfate
Drug
Lead sponsor
Sequus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 2:29 PM EDT
Terminated Phase 4 Interventional Results available

Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression

NCT01194856
View directory record Official record
Conditions
HIV Infection, Mitochondrial Dysfunction
Interventions
Atazanavir/ritonavir, Efavirenz
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Oct 25, 2026, 2:29 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Testing of a Navigation Intervention for Hepatitis C and HIV

NCT04499651
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus), Hepatitis C
Interventions
Navigation
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Not applicable Interventional Results available

Study to Evaluate Impact of School-based Influenza Vaccination on School Populations

NCT00844051
View directory record Official record
Conditions
Influenza
Interventions
School-based influenza vaccination program
Biological
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
4 Years to 18 Years
Enrollment
4,455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2016 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults

NCT00071851
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVDNA009-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cereset Research Long-Term Healthcare Worker Study

NCT05994261
View directory record Official record
Conditions
Stress, Anxiety, Autonomic Dysregulation, Acoustic Stimulation, Hyperarousal, Health Personnel
Interventions
Cereset Research
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 100 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 3 Interventional

The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs

NCT00002391
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Lamivudine, Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
3 Months to 12 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
30
States / cities
Birmingham, Alabama • Los Angeles, California • Fort Lauderdale, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 2:29 PM EDT
Active, not recruiting No phase listed Observational

A Study of Risk Factors for the COVID-19 Virus Infection

NCT04697927
View directory record Official record
Conditions
COVID-19 Infections in Cancer Patients
Interventions
Questionnaires
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
389 participants
Timeline
2020 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects

NCT02082808
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
DTG, DCV
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States

NCT05374525
View directory record Official record
Conditions
HIV Infections
Interventions
APRETUDE, Cabotegravir OLI
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older · Male only
Enrollment
287 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
17
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 25, 2026, 2:29 PM EDT
Recruiting Phase 1 Interventional

A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)

NCT04573140
View directory record Official record
Conditions
Adult Glioblastoma, High Grade Glioma, WHO Grade III or IV Malignant Glioma
Interventions
Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)
Biological
Lead sponsor
University of Florida
Other
Eligibility
4 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 4 Interventional Results available

Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines

NCT00993668
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Certolizumab pegol
Other · Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 25, 2026, 2:29 PM EDT
Active, not recruiting No phase listed Observational

NIH RECOVER Tissue Pathology: Understanding the Long-Term Impact of COVID-19

NCT05292274
View directory record Official record
Conditions
COVID-19, SARS CoV 2 Infection
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 1 Interventional

A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients

NCT00002218
View directory record Official record
Conditions
HIV Infections
Interventions
CI-1012
Drug
Lead sponsor
Parke-Davis
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Palm Springs, California • San Francisco, California • Maitland, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study With Proton Pump Inhibitor

NCT00357240
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Atazanavir/Ritonavir, Atazanavir/Ritonavir+Omeprazole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2011 · Synced Oct 25, 2026, 2:29 PM EDT